The new class of custom-built protein therapies, called Darpin, has antiviral effects. The companies will work together to develop MP0420, a multispecific Darpin anti-COVID-19 program. MP0420 has demonstrated therapeutic effects for existing COVID-19 viral infection in preliminary data, the companies noted.

Through the partnership, AGC Biologics will manufacture MP0420 in 100 liter and 1,000-liter scales. Molecular Partners AG plans to conduct clinical studies using the manufactured protein therapeutics later this year.

AGC Biologics expands plasmid manufacturing capacity
AGC Biologics is expanding its plasmid DNA Center of Excellence in Heidelberg, Germany, to meet the need for process development and manufacturing of...

Saiba selects AGC to manufacture COVID-19 vaccine
Contract development and manufacturing organization AGC Biologics said it will be manufacturing a SARS-CoV-2 vaccine for Swiss biotechnology firm Saiba.

AGC to manufacture adjuvant for Novavax COVID-19 vaccine
AGC Biologics announced it is partnering with Novavax for large-scale good manufacturing practices production of critical components for Novavax's coronavirus...

AGC acquires commercial manufacturing facility
Contract development and manufacturing organization AGC Biologics has purchased a large-scale biopharmaceutical manufacturing facility in Boulder, CO.

AGC to manufacture Takara Bio's COVID-19 vaccine
In the fight against COVID-19, AGC Biologics, a contract development and manufacturing organization, is partnering with Takara Bio to manufacture plasmid...